Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arthritis Res Ther
Glavni autori: Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://ncbi.nlm.nih.gov/pubmed/26283632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0721-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items